BBS5 — Bardet-Biedl syndrome 5

The BBS5 gene provides essential instructions for making a protein that is a key part of a structure called the BBSome. The BBSome acts like a cellular delivery service, specifically working within tiny, hair-like projections on the surface of cells called cilia. Cilia act as the cell's antennas, sensing the surrounding environment and sending important signals. In the eyes, specialized cilia are crucial for the cells that detect light, allowing us to see. The BBS5 protein helps ensure that the right materials are transported into and out of these cilia so they can function properly. When there is a mutation or mistake in the BBS5 gene, the BBSome delivery service breaks down. This means that the cilia cannot get the proteins they need to work correctly. In the eyes, this leads to the light-detecting cells slowly dying off, causing a condition called retinitis pigmentosa, which results in a progressive loss of vision. Because cilia are found all over the body, problems with the BBS5 gene also affect other organs, leading to a complex condition known as Bardet-Biedl syndrome (BBS). Patients with BBS may experience weight gain, extra fingers or toes, kidney problems, and learning difficulties. Bardet-Biedl syndrome caused by BBS5 mutations is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who typically each carry one mutated copy and one normal copy, are called carriers and usually do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child affected by the syndrome. Understanding this inheritance pattern is important for families when considering genetic testing and family planning.

Gene description: BBS5 encodes a BBSome component, crucial for ciliary assembly and function, mutations of which cause Bardet-Biedl syndrome.

Patient and family guide: The BBS5 gene provides essential instructions for making a protein that is a key part of a structure called the BBSome. The BBSome acts like a cellular delivery service, specifically working within tiny, hair-like projections on the surface of cells called cilia. Cilia act as the cell's antennas, sensing the surrounding environment and sending important signals. In the eyes, specialized cilia are crucial for the cells that detect light, allowing us to see. The BBS5 protein helps ensure that the right materials are transported into and out of these cilia so they can function properly. When there is a mutation or mistake in the BBS5 gene, the BBSome delivery service breaks down. This means that the cilia cannot get the proteins they need to work correctly. In the eyes, this leads to the light-detecting cells slowly dying off, causing a condition called retinitis pigmentosa, which results in a progressive loss of vision. Because cilia are found all over the body, problems with the BBS5 gene also affect other organs, leading to a complex condition known as Bardet-Biedl syndrome (BBS). Patients with BBS may experience weight gain, extra fingers or toes, kidney problems, and learning difficulties. Bardet-Biedl syndrome caused by BBS5 mutations is inherited in an autosomal recessive pattern. This means that a person must inherit two mutated copies of the gene—one from each parent—to develop the condition. The parents, who typically each carry one mutated copy and one normal copy, are called carriers and usually do not show any symptoms of the disease. If both parents are carriers, there is a 25% chance with each pregnancy of having a child affected by the syndrome. Understanding this inheritance pattern is important for families when considering genetic testing and family planning.

Gene function: BBS5 plays a key role in the BBSome complex, which is essential for the proper formation and maintenance of cilia in retinal photoreceptor cells. Cilia are vital for transporting proteins and other molecules to the outer segments, where light is detected. Dysfunction of BBS5 impairs this transport, leading to the degeneration of photoreceptors and subsequent vision loss in affected individuals.

Protein structure: The BBS5 protein is a 341-amino acid polypeptide that forms an integral part of the BBSome complex. Structurally, BBS5 is characterized by the presence of two pleckstrin homology (PH)-like domains. These domains are critical for the protein's function, as they mediate the binding of BBS5 to phosphoinositides, specifically phosphatidylinositol 3-phosphate (PI(3)P). This lipid-binding capability is essential for anchoring the BBSome to specific membrane compartments within the cell, facilitating its role in vesicular trafficking to and from the primary cilium. Within the BBSome, an octameric complex comprising BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, and BBIP10, BBS5 interacts closely with other core members to maintain the structural stability and functional integrity of the complex. The assembly of the BBSome is a highly coordinated process, and the incorporation of BBS5 is necessary for the complex to properly associate with the ciliary membrane. While specific post-translational modifications of BBS5 have not been extensively detailed, its stable integration into the BBSome is a prerequisite for its biological activity in ciliary protein sorting and transport.

Molecular function: The BBS5 gene encodes a core component of the BBSome, a highly conserved octameric protein complex essential for the proper function and maintenance of primary cilia. The primary molecular function of the BBSome is to act as a specialized coat complex that regulates the trafficking of specific membrane proteins into and out of the ciliary compartment. BBS5, along with other core BBS proteins, forms a stable complex that interacts with the ciliary membrane and facilitates the sorting of cargo proteins. A critical aspect of BBS5 function involves its interaction with phosphoinositides, specifically phosphatidylinositol 3-phosphate (PI(3)P). BBS5 contains domains that bind to PI(3)P, which is thought to anchor the BBSome to specific membrane domains, facilitating its role in vesicular trafficking. The BBSome is required for the ciliary localization of various signaling receptors, including those involved in the Sonic Hedgehog (Shh) and G-protein coupled receptor (GPCR) pathways. In photoreceptor cells, the BBSome is crucial for the transport of rhodopsin and other essential outer segment proteins across the connecting cilium. Disruption of BBS5 function leads to the destabilization of the BBSome complex and subsequent defects in ciliary protein trafficking. This impairment results in the mislocalization of ciliary proteins, defective ciliogenesis, and the disruption of cilia-dependent signaling pathways. In the retina, the failure to properly transport outer segment proteins leads to the accumulation of these proteins in the inner segment, ultimately causing photoreceptor cell death and the progressive retinal degeneration characteristic of Bardet-Biedl syndrome.

Expression pattern: The BBS5 gene is ubiquitously expressed across a wide range of tissues, reflecting its fundamental role in the formation and function of primary cilia, which are present on nearly all mammalian cell types. High levels of expression are particularly noted in tissues that are heavily reliant on ciliary function, such as the retina, brain, kidney, and olfactory epithelium. In the retina, BBS5 is prominently expressed in the photoreceptor cells, specifically localizing to the connecting cilium, a specialized structure essential for the transport of proteins between the inner and outer segments. During development, BBS5 expression is critical for proper organogenesis and tissue patterning, processes that are heavily dependent on cilia-mediated signaling pathways like Sonic Hedgehog (Shh). Alternative splicing of the BBS5 transcript can generate different protein isoforms, which may have tissue-specific roles or regulatory functions. For instance, a smaller splice variant of the BBS5 protein has been identified, suggesting that alternative splicing may contribute to the functional diversity of the BBSome complex in different cellular contexts.

Mutation spectrum: The mutation spectrum of the BBS5 gene encompasses a variety of pathogenic variants, including missense, nonsense, frameshift, and splice-site mutations, as well as larger structural variations such as deletions. These mutations are distributed throughout the gene, and while some recurrent mutations have been identified in specific populations, there is no single predominant hotspot for BBS5 mutations globally. The majority of these variants lead to a loss of function of the BBS5 protein, either through premature truncation or by disrupting critical functional domains necessary for BBSome assembly or membrane binding. BBS5 mutations are a relatively rare cause of Bardet-Biedl syndrome, accounting for approximately 2% of all BBS cases. The ClinVar database and other genetic repositories list numerous pathogenic and likely pathogenic variants associated with the gene. In certain isolated or consanguineous populations, specific founder mutations in BBS5 may be more prevalent, contributing to a higher local incidence of the disease. The identification of both point mutations and larger copy number variations underscores the need for comprehensive genetic testing approaches to accurately diagnose BBS5-related disorders.

Pathogenic variants: 1. p.Arg122Ter (c.364C>T): A nonsense mutation that introduces a premature stop codon, leading to a truncated and non-functional protein. This variant is a well-characterized cause of classic Bardet-Biedl syndrome. 2. p.Gly144Arg (c.430G>A): A missense mutation that substitutes a highly conserved glycine residue with arginine. This alteration is predicted to disrupt the structural integrity or binding capabilities of the BBS5 protein, contributing to the BBS phenotype. 3. p.Leu242Pro (c.725T>C): Another missense variant that replaces leucine with proline, likely affecting the protein's folding or its interaction with other BBSome components. 4. c.432+1G>A: A canonical splice-site mutation that disrupts normal pre-mRNA splicing, leading to an aberrant transcript and subsequent loss of functional BBS5 protein. 5. Exon 1-3 deletion: A large structural variant involving the deletion of the first three exons of the BBS5 gene, resulting in a complete loss of function and severe clinical manifestations.

Clinical significance: Mutations in the BBS5 gene are a rare cause of Bardet-Biedl syndrome (BBS), a complex, multisystem ciliopathy. The clinical manifestation of BBS5 mutations is characterized by a spectrum of primary and secondary features. The most penetrant and defining feature is early-onset, progressive retinal dystrophy, typically presenting as cone-rod dystrophy. Patients often experience night blindness in childhood, followed by a progressive loss of peripheral vision and visual acuity, frequently leading to legal blindness by the second or third decade of life. Beyond the ocular phenotype, individuals with BBS5 mutations commonly present with central obesity, which typically develops in the first year of life. Postaxial polydactyly, cognitive impairment, and hypogonadism are also frequent clinical findings. Renal anomalies represent a significant source of morbidity and mortality in these patients, ranging from structural malformations to progressive chronic kidney disease. The severity and specific combination of these features can vary significantly among affected individuals, even within the same family, highlighting the complex clinical expressivity of the syndrome.

Inheritance: Autosomal Recessive

Chromosomal location: 2q31.1

Genotype-phenotype correlations: Genotype-phenotype correlations in Bardet-Biedl syndrome, including cases caused by BBS5 mutations, are complex and often challenging to establish definitively. While BBS5 mutations generally lead to the classic BBS phenotype, the severity and specific combination of symptoms can vary widely. Some studies suggest that truncating mutations (such as nonsense or frameshift variants) may be associated with a more severe and earlier-onset clinical presentation compared to missense mutations, which might retain partial protein function. However, the high degree of clinical variability observed even among individuals with the same BBS5 genotype indicates that other factors, such as genetic modifiers or environmental influences, play a significant role in shaping the phenotype. The concept of triallelic inheritance, where a mutation in a second BBS gene modifies the expression of the primary disease-causing mutations, has been proposed in BBS, further complicating genotype-phenotype predictions. Therefore, while the specific BBS5 mutation can provide some prognostic information, clinical management must be tailored to the individual patient's specific manifestations.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies that can cure or halt the progression of the underlying disease in individuals with BBS5 mutations. Management of Bardet-Biedl syndrome is primarily supportive and multidisciplinary, focusing on treating the specific symptoms and complications as they arise. For the retinal degeneration aspect, interventions are limited to low-vision aids, orientation and mobility training, and educational support to maximize the patient's remaining vision and quality of life. Regular monitoring by an ophthalmologist is essential to track disease progression and manage any secondary complications, such as cataracts or macular edema. Research into targeted therapeutic approaches for BBS, including those caused by BBS5 mutations, is ongoing. Gene therapy holds significant promise for inherited retinal diseases, as demonstrated by the approval of Luxturna for RPE65-associated dystrophy. While specific gene therapy trials for BBS5 are not yet in advanced clinical stages, preclinical studies using viral vectors to deliver functional copies of BBS genes to the retina in animal models have shown potential in preserving photoreceptor function and structure. Additionally, research is exploring the use of pharmacological agents to address the systemic features of BBS. For instance, recent studies in Bbs5 knockout mouse models have investigated the use of GLP-1 receptor agonists, which have shown efficacy in improving metabolic function, reducing food intake, and mitigating obesity, suggesting a potential therapeutic avenue for managing the metabolic complications of the syndrome.

Diagnostic testing: Diagnostic testing for BBS5 mutations typically involves comprehensive genetic analysis, given the genetic heterogeneity of Bardet-Biedl syndrome. Next-generation sequencing (NGS) approaches, such as targeted multi-gene panels for ciliopathies or inherited retinal dystrophies, are commonly employed as the first-line diagnostic tool. These panels simultaneously sequence BBS5 and other known BBS-associated genes, allowing for efficient identification of pathogenic variants. In cases where targeted panels are uninformative, whole exome sequencing (WES) or whole genome sequencing (WGS) may be utilized to detect novel or complex structural variants, including large deletions or duplications that might be missed by standard sequencing methods. Genetic counseling is a crucial component of the diagnostic process for individuals and families affected by BBS5 mutations. Since BBS follows an autosomal recessive inheritance pattern, parents of an affected individual are typically obligate carriers, with a 25% chance of having another affected child in subsequent pregnancies. Genetic counselors provide essential information regarding the inheritance pattern, the natural history of the disease, and the potential for variable expressivity. They also discuss the implications of genetic test results for family planning and facilitate access to appropriate medical surveillance and supportive therapies.

Animal models: Animal models, particularly mouse models, have been instrumental in understanding the function of BBS5 and the pathophysiology of Bardet-Biedl syndrome. The Bbs5 knockout mouse model (Bbs5-/-) closely mirrors the human BBS phenotype, exhibiting characteristic features such as retinal degeneration, obesity, and olfactory deficits. These models have revealed that the loss of Bbs5 disrupts the BBSome complex, leading to defective ciliary trafficking and structural abnormalities in primary cilia across various tissues. In the retina, Bbs5-/- mice show progressive photoreceptor degeneration, highlighting the gene's critical role in the maintenance and function of the connecting cilium in photoreceptor cells. Furthermore, these models have been used to investigate the metabolic aspects of the syndrome, demonstrating that Bbs5 deficiency leads to hyperphagia and altered energy homeostasis. Recent studies utilizing these models have also explored potential therapeutic interventions, such as GLP-1 receptor agonists, which have shown promise in rescuing metabolic phenotypes and reducing obesity in Bbs5-deficient mice.

Population genetics: Mutations in the BBS5 gene are a rare cause of Bardet-Biedl syndrome, which itself has an estimated prevalence of 1 in 100,000 to 1 in 160,000 individuals in most populations of European descent. BBS5 mutations account for only about 2% of all genetically confirmed BBS cases, making it one of the less frequently implicated genes in the syndrome. However, the prevalence of BBS and specific BBS5 mutations can be significantly higher in certain isolated populations or communities with high rates of consanguinity, such as the Bedouin populations in the Middle East or specific communities in Newfoundland, Canada, due to founder effects. In the general population, the carrier frequency for BBS5 mutations is very low, reflecting the overall rarity of the condition.

Selected references: 1. Forsyth RL, et al. Bardet-Biedl Syndrome Overview. GeneReviews. 2023. PMID: 20301537 2. Nachury MV, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell. 2007. PMID: 17588924 3. Daniels AB, et al. Genotype-phenotype correlations in Bardet-Biedl syndrome. JAMA Ophthalmol. 2012. PMID: 22410627 4. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013. PMID: 23249954 5. Bolch SN, et al. A Splice Variant of Bardet-Biedl Syndrome 5 (BBS5) Protein that is Conserved in Vertebrates. PLoS One. 2016. PMID: 26849434 6. Singh A, et al. Transcriptome-guided GLP-1 receptor therapy rescues metabolic phenotypes in a Bbs5-knockout model. J Clin Invest. 2025. PMID: 38230654